Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2023

Open Access 05-05-2023 | Hepatocellular Carcinoma | Case report

Totally laparoscopic associating simultaneous bile duct and portal vein ligation for planned hepatectomy for primary liver cancer: a case report

Authors: Wang Jinghan, Ao Jianyang, Ma Wencong, Liu Chen

Published in: Journal of Medical Case Reports | Issue 1/2023

Login to get access

Abstract

Background

Some patients with liver cancer lose the chance to have surgical treatment due to insufficient future remnant liver. To address this problem, individual or occlusion of both the portal vein and the bile duct was used to achieve quick hypertrophy. This is the first study reported in which simultaneous ligation of the portal vein and the bile duct was applied as the first step of planned hepatectomy of primary liver cancer.

Case presentation

Here we report a case of a 38-year-old Asian male patient with hepatocellular carcinoma with tumor thrombus in the right anterior branch of the portal vein. Right hemihepatectomy can be curative, but patients face a high risk of liver failure because of the small volume of the remaining left liver lobe. Hence we developed a two-step liver resection strategy in which the patient underwent laparoscopic simultaneous bile duct and portal vein ligation of the right hepatic lobe prior to right hemihepatectomy under laparoscopy. Using this procedure, we achieved fast hypertrophy of the left liver lobe and successfully reversed the primary unresectability.

Conclusion

This case report demonstrates that simultaneous bile duct and portal vein ligation may be a feasible option for those patients with liver cancer who cannot get surgical treatment due to insufficient future remnant liver.
Literature
1.
go back to reference Kawaguchi Y, Lillemoe HA, Vauthey JN. Dealing with an insufficient future liver remnant: portal vein embolization and two-stage hepatectomy. J Surg Oncol. 2019;119(5):594–603.CrossRefPubMedPubMedCentral Kawaguchi Y, Lillemoe HA, Vauthey JN. Dealing with an insufficient future liver remnant: portal vein embolization and two-stage hepatectomy. J Surg Oncol. 2019;119(5):594–603.CrossRefPubMedPubMedCentral
2.
go back to reference Lopez-Lopez V, Robles-Campos R, Brusadin R, Lopez-Conesa A, de la Pena J, Caballero A, Arevalo-Perez J, Navarro-Barrios A, Gomez P, Parrilla-Paricio P. ALPPS for hepatocarcinoma under cirrhosis: a feasible alternative to portal vein embolization. Ann Transl Med. 2019;7(22):691.CrossRefPubMedPubMedCentral Lopez-Lopez V, Robles-Campos R, Brusadin R, Lopez-Conesa A, de la Pena J, Caballero A, Arevalo-Perez J, Navarro-Barrios A, Gomez P, Parrilla-Paricio P. ALPPS for hepatocarcinoma under cirrhosis: a feasible alternative to portal vein embolization. Ann Transl Med. 2019;7(22):691.CrossRefPubMedPubMedCentral
3.
go back to reference Ren W, Chen G, Wang X, Zhang A, Li C, Lv W, Pan K, Dong JH. Simultaneous bile duct and portal vein ligation induces faster atrophy/hypertrophy complex than portal vein ligation: role of bile acids. Sci Rep. 2015;5:8455.CrossRefPubMedPubMedCentral Ren W, Chen G, Wang X, Zhang A, Li C, Lv W, Pan K, Dong JH. Simultaneous bile duct and portal vein ligation induces faster atrophy/hypertrophy complex than portal vein ligation: role of bile acids. Sci Rep. 2015;5:8455.CrossRefPubMedPubMedCentral
4.
go back to reference Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunven P, Yamazaki S, Hasegawa H, Ozaki H. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery. 1990;107(5):521–7.PubMed Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunven P, Yamazaki S, Hasegawa H, Ozaki H. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery. 1990;107(5):521–7.PubMed
5.
go back to reference Honjo I, Suzuki T. Right or left portal branch ligation for liver cancer. Gan No Rinsho. 1970;16(6):567–73.PubMed Honjo I, Suzuki T. Right or left portal branch ligation for liver cancer. Gan No Rinsho. 1970;16(6):567–73.PubMed
6.
go back to reference Honjo I, Suzuki T, Ozawa K, Takasan H, Kitamura O. Evaluation of ligation of a branch of the portal vein for unresectable hepatic tumor. Bull Soc Int Chir. 1974;33(3):207–10.PubMed Honjo I, Suzuki T, Ozawa K, Takasan H, Kitamura O. Evaluation of ligation of a branch of the portal vein for unresectable hepatic tumor. Bull Soc Int Chir. 1974;33(3):207–10.PubMed
7.
go back to reference Kianmanesh R, Farges O, Abdalla EK, Sauvanet A, Ruszniewski P, Belghiti J. Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases. J Am Coll Surg. 2003;197(1):164–70.CrossRefPubMed Kianmanesh R, Farges O, Abdalla EK, Sauvanet A, Ruszniewski P, Belghiti J. Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases. J Am Coll Surg. 2003;197(1):164–70.CrossRefPubMed
8.
go back to reference Iida H, Yasui C, Aihara T, Ikuta S, Yoshie H, Yamanaka N. Simultaneous bile duct and portal venous branch ligation in two-stage hepatectomy. World J Gastroenterol. 2011;17(30):3554–9.CrossRefPubMedPubMedCentral Iida H, Yasui C, Aihara T, Ikuta S, Yoshie H, Yamanaka N. Simultaneous bile duct and portal venous branch ligation in two-stage hepatectomy. World J Gastroenterol. 2011;17(30):3554–9.CrossRefPubMedPubMedCentral
Metadata
Title
Totally laparoscopic associating simultaneous bile duct and portal vein ligation for planned hepatectomy for primary liver cancer: a case report
Authors
Wang Jinghan
Ao Jianyang
Ma Wencong
Liu Chen
Publication date
05-05-2023
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2023
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-023-03859-4

Other articles of this Issue 1/2023

Journal of Medical Case Reports 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine